Spatial phenotyping of nodular lymphocyte predominant Hodgkin lymphoma and T-cell/histiocyte-rich large B-cell lymphoma.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
31 May 2024
31 May 2024
Historique:
received:
18
11
2023
accepted:
16
05
2024
revised:
10
05
2024
medline:
1
6
2024
pubmed:
1
6
2024
entrez:
31
5
2024
Statut:
epublish
Résumé
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma with sparse tumor B-cells and a favorable prognosis. Variant growth patterns of NLPHL, however, often show advanced stage, progression to T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) and a worse prognosis. We studied the tumor microenvironment (TME) of NLPHL and THRLBCL using highplex imaging and spatial profiling at the single cell level. Our findings show distinct differences in TME composition and spatial configuration that differ among typical and variant NLPHL and THRLBCL. Typical NLPHL show abundant helper T-cell subsets, while THRLBCL show abundant cytotoxic T-cells and macrophages. Tumor B-cell size and content is lowest in typical NLPHL, followed by variant NLPHL, and highest in THRLBCL, whereas an opposite trend characterized TME B-cells. CD4/CD8 double-positive T-cells are seen in all NLPHL but not in the majority of THRLBCL and are spatially distant from LP-cells and TFH-rosettes. The differences in macrophage/monocyte content in distinguishing NLPHL pattern E from THRLBCL is further corroborated in independent cohorts of cases. Our results validate the current approach to classification and in addition provide novel insights that could be leveraged to refine clinical management for patients with this spectrum of lymphomas.
Identifiants
pubmed: 38821935
doi: 10.1038/s41408-024-01073-z
pii: 10.1038/s41408-024-01073-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
92Informations de copyright
© 2024. The Author(s).
Références
Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107:265–76.
pubmed: 16150940
pmcid: 1895348
doi: 10.1182/blood-2005-06-2508
Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 2016;66:443–59.
pubmed: 27618563
doi: 10.3322/caac.21357
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(Jul):1720–48.
pubmed: 35732829
pmcid: 9214472
doi: 10.1038/s41375-022-01620-2
Al-Mansour M, Connors JM, Gascoyne RD, Skinnider B, Savage KJ. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin’s lymphoma. J Clin Oncol. 2010;28:793–9.
pubmed: 20048177
doi: 10.1200/JCO.2009.24.9516
Biasoli I, Stamatoullas A, Meignin V, Delmer A, Reman O, Morschhauser F, et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer. 2010;116:631–9.
pubmed: 20029973
doi: 10.1002/cncr.24819
Hartmann S, Döring C, Jakobus C, Rengstl B, Newrzela S, Tousseyn T, et al. Nodular Lymphocyte Predominant Hodgkin Lymphoma and T Cell/Histiocyte Rich Large B Cell Lymphoma—Endpoints of a Spectrum of One Disease? PLoS One. 2013;8:e78812.
pubmed: 24244368
pmcid: 3823948
doi: 10.1371/journal.pone.0078812
Eyre TA, Gatter K, Collins GP, Hall GW, Watson C, Hatton CS. Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant Hodgkin lymphoma: Long-term outcomes from a 30-year experience. Am J Hematol. 2015;90:E103–E110.
pubmed: 25715900
doi: 10.1002/ajh.23989
Eichenauer DA, Plütschow A, Fuchs M, von Tresckow B, Böll B, Behringer K, et al. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group. J Clin Oncol. 2015;33:2857–62.
pubmed: 26240235
doi: 10.1200/JCO.2014.60.4363
Kenderian SS, Habermann TM, Macon WR, Ristow KM, Ansell SM, Colgan JP, et al. Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. Blood. 2016;127:1960–6.
pubmed: 26837698
pmcid: 4841039
doi: 10.1182/blood-2015-08-665505
Shankar AG, Roques G, Kirkwood AA, Lambilliotte A, Freund K, Leblanc T, et al. Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: Clinical characteristics and treatment outcome—A report from the SFCE & CCLG groups. Br J Haematol. 2017;177:106–15.
pubmed: 28220934
doi: 10.1111/bjh.14518
Marks LJ, Pei Q, Bush R, Buxton A, Appel B, Kelly KM, et al. Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children’s Oncology Group. Pediatr Blood Cancer. 2018;65:e27375.
pubmed: 30277639
pmcid: 6192844
doi: 10.1002/pbc.27375
Binkley MS, Rauf MS, Milgrom SA, Pinnix CC, Tsang R, Dickinson M, et al. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: A multi-institutional study of adult patients by ILROG. Blood. 2020;135:2365–74.
pubmed: 32211877
doi: 10.1182/blood.2019003877
Eichenauer DA, Plütschow A, Fuchs M, Sasse S, Baues C, Böll B, et al. Long-Term Follow-Up of Patients with Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group. J Clin Oncol. 2020;38:698–705.
pubmed: 31626571
doi: 10.1200/JCO.19.00986
Paschold L, Willscher E, Bein J, Vornanen M, Eichenauer DA, Simnica D, et al. Evolutionary clonal trajectories in nodular lymphocyte-predominant Hodgkin lymphoma with high risk of transformation. Haematologica. 2021;106:2654–66.
pubmed: 33882641
pmcid: 8485677
doi: 10.3324/haematol.2021.278427
Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA. Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol. 2003;27:1346–56.
pubmed: 14508396
doi: 10.1097/00000478-200310000-00007
Hartmann S, Eichenauer DA, Plütschow A, Mottok A, Bob R, Koch K, et al. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2013;19:4246–52.
doi: 10.1182/blood-2013-07-515825
Hartmann S, Eichenauer DA. Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphoma. Pathology. 2020;52:142–53.
pubmed: 31785822
doi: 10.1016/j.pathol.2019.10.003
Xia D, Sayed S, Moloo Z, Gakinya SM, Mutuiri A, Wawire J, et al. Geographic variability of nodular lymphocyte-predominant Hodgkin Lymphoma. Am J Clin Pathol. 2022;157:231–43.
pubmed: 34542569
doi: 10.1093/ajcp/aqab113
El Weshi A, Akhtar S, Mourad WA, Ajarim D, Abdelsalm M, Khafaga Y, et al. T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: Report on 61 patients and review of literature. Leuk Lymphoma. 2007;48:1764–73.
pubmed: 17786712
doi: 10.1080/10428190701559124
Bouabdallah R, Mounier N, Guettier C, Molina T, Ribrag V, Thieblemont C, et al. T-Cell/Histiocyte-Rich Large B-Cell Lymphomas and Classical Diffuse Large B-Cell Lymphomas Have Similar Outcome After Chemotherapy: A Matched-Control Analysis. J Clin Oncol. 2003;21:1271–7.
pubmed: 12663714
doi: 10.1200/JCO.2003.06.046
Franke S, Wlodarska I, Maes B, Vandenberghe P, Delabie J, Hagemeijer A, et al. Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances. Blood. 2001;97:1845–53.
pubmed: 11238128
doi: 10.1182/blood.V97.6.1845
Franke S, Wlodarska I, Maes B, Vandenberghe P, Achten R, Hagemeijer A, et al. Comparative genomic hybridization pattern distinguishes T-cell/histiocyte-rich B-cell lymphoma from nodular lymphocyte predominance Hodgkin’s lymphoma. Am J Pathol. 2002;161:1861–7.
pubmed: 12414532
pmcid: 1850793
doi: 10.1016/S0002-9440(10)64462-8
Goltsev Y, Samusik N, Kennedy-Darling J, Bhate S, Hale M, Vazquez G, et al. Deep Profiling of Mouse Splenic Architecture With CODEX Multiplexed Imaging. Cell. 2018;174:968–81.
pubmed: 30078711
pmcid: 6086938
doi: 10.1016/j.cell.2018.07.010
Schürch CM, Bhate SS, Barlow GL, Phillips DJ, Noti L, Zlobec I, et al. Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front. Cell. 2020;182:1341–59.e19.
pubmed: 32763154
pmcid: 7479520
doi: 10.1016/j.cell.2020.07.005
Phillips D, Matusiak M, Gutierrez BR, Bhate SS, Barlow GL, Jiang S, et al. Immune Cell Topography Predicts Response to PD-1 Blockade in Cutaneous T Cell Lymphoma. Nat Commun. 2021;12:6721.
doi: 10.1038/s41467-021-26974-6
Phillips D, Schürch CM, Khodadoust MS, Kim YH, Nolan GP, Jiang S. Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging. Front Immunol. 2021;12:687673.
pubmed: 34093591
pmcid: 8170307
doi: 10.3389/fimmu.2021.687673
Brune V, Tiacci E, Pfeil I, Döring C, Eckerle S, van Noesel CJ, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med. 2008;205:2251–2268.
pubmed: 18794340
pmcid: 2556780
doi: 10.1084/jem.20080809
Du Z, Lin JR, Rashid R, Maliga Z, Wang S, Aster JC, et al. Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. Nat Protoc. 2019;14:2900–30.
pubmed: 31534232
pmcid: 6959005
doi: 10.1038/s41596-019-0206-y
Spidlen J, Moore W, Parks D, Goldberg M, Bray C, Bierre P, et al. Data File Standard for Flow Cytometry, version FCS 3.1. Cytom A. 2010;77:97–100.
doi: 10.1002/cyto.a.20825
Satija R, Farrell JA, Gennert D, Schier AF, Regev A. Spatial reconstruction of single-cell gene expression data. Nat Biotechnol. 2015;33:495–502.
pubmed: 25867923
pmcid: 4430369
doi: 10.1038/nbt.3192
Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nature Biotechnol. 2018;36:411–20.
Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM 3rd, et al. Comprehensive Integration of Single-Cell Data. Cell. 2019;177:1888–902.
pubmed: 31178118
pmcid: 6687398
doi: 10.1016/j.cell.2019.05.031
Hao Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, Zheng S, Butler A, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184:3573–87.
pubmed: 34062119
pmcid: 8238499
doi: 10.1016/j.cell.2021.04.048
Zhang X, Tsang P. 196 IMP3/KOC1, a new immunohistochemical marker for differentiating classical Hodgkin Lymphoma and nodular lymphocyte predominant Hodgkin lymphoma from diffuse large B-Cell lymphoma. Am J Clin Pathol. 2018;149:S83–S84.
doi: 10.1093/ajcp/aqx121.195
Kosari F, Bakhshi T, Ameli F, Mokhtari M. The utility of IMP3 immunohistochemical staining in differentiating nodular lymphocyte predominant Hodgkin Lymphoma from T-Cell/Histiocyte-Rich large B-Cell lymphoma. BMC Cancer. 2022;22:1359.
pubmed: 36577979
pmcid: 9795661
doi: 10.1186/s12885-022-10321-z
Poppe B, De Paepe P, Michaux L, Dastugue N, Bastard C, Herens C, et al. PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements. Genes Chromosomes Cancer. 2005;44:218–23.
pubmed: 15942942
doi: 10.1002/gcc.20214
Hartmann S, Döring C, Vucic E, Chan FC, Ennishi D, Tousseyn T, et al. Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma. Br J Haematol. 2015;169:415–22.
pubmed: 25644177
doi: 10.1111/bjh.13310
Hartmann S, Schuhmacher B, Rausch T, Fuller L, Döring C, Weniger M, et al. Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma. Leukemia. 2016;30:844–53.
pubmed: 26658840
doi: 10.1038/leu.2015.328
Song JY, Egan C, Bouska AC, Zhang W, Gong Q, Venkataraman G, et al. Genomic characterization of diffuse large B-cell lymphoma transformation of nodular lymphocyte-predominant Hodgkin lymphoma. Leukemia. 2020;34:2238–42.
pubmed: 32054999
pmcid: 8499090
doi: 10.1038/s41375-020-0739-7
Schuhmacher B, Bein J, Rausch T, Benes V, Tousseyn T, Vornanen M, et al. JUNB, DUSP2, SGK1, SOCS1 and CREBBP are frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma. Haematologica. 2019;104:330–7.
pubmed: 30213827
pmcid: 6355500
doi: 10.3324/haematol.2018.203224
Bein J, Thurner L, Hansmann ML, Hartmann S. Lymphocyte predominant cells of nodular lymphocyte predominant Hodgkin lymphoma interact with rosetting T cells in an immunological synapse. Am J Hematol. 2020;95:1495–502.
pubmed: 32815561
doi: 10.1002/ajh.25972
Veldman J, Alsada ZND, van den Berg A, Plattel WJ, Diepstra A, Visser L. Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma. Br J Haematol. 2021;193:506–14.
pubmed: 33620088
pmcid: 8247981
doi: 10.1111/bjh.17362
Nam-Cha SH, Roncador G, Sanchez-Verde L, Montes-Moreno S, Acevedo A, Domínguez-Franjo P, et al. PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma. Am J Surg Pathol. 2008;32:1252–7.
pubmed: 18594468
doi: 10.1097/PAS.0b013e318165b0d6
Churchill HR, Roncador G, Warnke RA, Natkunam Y. Programmed death 1 expression in variant immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma: comparison with CD57 and lymphomas in the differential diagnosis. Hum Pathol. 2010;41:1726–34.
pubmed: 20825974
doi: 10.1016/j.humpath.2010.05.010
Visser L, Rutgers B, Diepstra A, van den Berg A, Sattarzadeh A. Characterization of the microenvironment of nodular lymphocyte predominant Hodgkin lymphoma. Int J Mol Sci. 2016;17:2127.
pubmed: 27999289
pmcid: 5187927
doi: 10.3390/ijms17122127
Mita Y, Kimura MY, Hayashizaki K, Koyama-Nasu R, Ito T, Motohashi S, et al. Crucial role of CD69 in anti-tumor immunity through regulating the exhaustion of tumor-infiltrating T cells. Int Immunol. 2018;30:559–67.
pubmed: 30085193
doi: 10.1093/intimm/dxy050
Younes S, Rojansky RB, Menke JR, Gratzinger D, Natkunam Y. Pitfalls in the Diagnosis of Nodular Lymphocyte Predominant Hodgkin Lymphoma: Variant Patterns, Borderlines and Mimics. Cancers. 2021;13:3021.
pubmed: 34208705
pmcid: 8234802
doi: 10.3390/cancers13123021
Eladl AE, Satou A, Elsayed AA, Suzuki Y, Shimizu-Kohno K, Kato S, et al. Nodular lymphocyte predominant Hodgkin lymphoma: Clincopathological study of 25 cases from Japan with a reappraisal of tissue associated macrophages. Pathol Int. 2015;65:652–60.
pubmed: 26538151
doi: 10.1111/pin.12357
Autio M, Leivonen SK, Brück O, Karjalainen-Lindsberg ML, Pellinen T, Leppä S. Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment. Clin Cancer Res. 2022;28:781–92.
pubmed: 34907083
doi: 10.1158/1078-0432.CCR-21-3140
Chemnitz JM, Eggle D, Driesen J, Classen S, Riley JL, Debey-Pascher S, et al. RNA fingerprints provide direct evidence for the inhibitory role of TGF and PD-1 on CD4 T cells in Hodgkin lymphoma. Blood. 2007;110:3226–33.
pubmed: 17644739
doi: 10.1182/blood-2006-12-064360
Vermare A, Guérin MV, Peranzoni E, Bercovici N. Dynamic CD8+ T Cell Cooperation with Macrophages and Monocytes for Successful Cancer Immunotherapy. Cancers. 2022;14:3546.
pubmed: 35884605
pmcid: 9318008
doi: 10.3390/cancers14143546
Rahemtullah A, Harris NL, Dorn ME, Preffer FI, Hasserjian RP. Beyond the lymphocyte predominant cell: CD4+CD8+ T-cells in nodular lymphocyte predominant Hodgkin lymphoma. Leuk Lymphoma. 2008;49:1870–8.
pubmed: 18949610
doi: 10.1080/10428190802308728
Hartmann S, Soltani AS, Bankov K, Bein J, Hansmann ML, Rosenwald A, et al. Tumour cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma. Br J Hematol. 2022;199:382–91.
doi: 10.1111/bjh.18376
Sadeghi Shoreh Deli A, Scharf S, Steiner Y, Bein J, Hansmann ML, Hartmann S. 3D analyses reveal T cells with activated nuclear features in T-cell/histiocyte-rich large B-cell lymphoma. Mod Pathol. 2022;35:1431–8.
pubmed: 35173297
pmcid: 9514992
doi: 10.1038/s41379-022-01016-8